Bank of America’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-97,000
| Closed | -$451K | – | 7497 |
|
|
2017
Q4 | $451K | Buy |
+97,000
| New | +$535K | ﹤0.01% | 5006 |
|
|
2017
Q1 | – | Sell |
-23,100
| Closed | -$135K | – | 7431 |
|
|
2016
Q4 | $135K | Hold |
23,100
| – | – | ﹤0.01% | 5493 |
|
|
2016
Q3 | $123K | Hold |
23,100
| – | – | ﹤0.01% | 5349 |
|
|
2016
Q2 | $153K | Hold |
23,100
| – | – | ﹤0.01% | 5336 |
|
|
2016
Q1 | $108K | Sell |
23,100
-247,700
| -91% | -$989K | ﹤0.01% | 5449 |
|
|
2015
Q4 | $1.37M | Buy |
270,800
+23,100
| +9% | +$110K | ﹤0.01% | 4127 |
|
|
2015
Q3 | $872K | Buy |
247,700
+222,700
| +891% | +$1.49M | ﹤0.01% | 4428 |
|
|
2015
Q2 | $250K | Buy |
+25,000
| New | +$268K | ﹤0.01% | 5130 |
|
|
2015
Q1 | – | Sell |
-2,000
| Closed | -$28K | – | 7813 |
|
|
2014
Q4 | $28K | Sell |
2,000
-231,000
| -99% | -$3.58M | ﹤0.01% | 6641 |
|
|
2014
Q3 | $3.2M | Buy |
233,000
+228,000
| +4,560% | +$3.49M | ﹤0.01% | 2966 |
|
|
2014
Q2 | $77K | Sell |
5,000
-1,400
| -22% | -$19.8K | ﹤0.01% | 6337 |
|
|
2014
Q1 | $109K | Sell |
6,400
-38,300
| -86% | -$578K | ﹤0.01% | 5931 |
|
|
2013
Q4 | $579K | Buy |
44,700
+23,100
| +107% | +$276K | ﹤0.01% | 4633 |
|
|
2013
Q3 | $218K | Buy |
21,600
+13,700
| +173% | +$122K | ﹤0.01% | 5373 |
|
|
2013
Q2 | $59K | Buy |
+7,900
| New | +$61.7K | ﹤0.01% | 6472 |
|
Bank of America's KERX Position: Q4 2018 in Review
Bank of America sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 163,226 shares — an estimated $555K sold.
Bank of America first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $4.13M in Q3 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Bank of America reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Bank of America sold 163,226 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $555K.
- Bank of America first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Bank of America's Keryx Biopharmaceuticals Inc position peaked at $4.13M in Q3 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Bank of America's 13F filing for Q4 2018, filed 14 Feb 2019.